Skip to content

Ocular Therapeutix

US · OCUL #2978 by market cap Listed 1970
5.57 -0.29 -4.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Announces Target Price $9.32
    Market Newswire · 2026/4/29
  • Rating change
    Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31
    Market Newswire · 2026/10/12
  • Rating change
    William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating
    Market Newswire · 2026/9/26
  • Rating change
    TD Cowen Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/8/4
  • RBC Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/10
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Zenas BioPharma, Inc. (ZBIO), Ocular Therapeutix (OCUL)
    TipRanks · 2026/10/13
  • Rating change
    A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $31
    Market Newswire · 2026/6/19
  • Needham Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/11/10
  • Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q3 Revenue $12.9M, Vs. FactSet Est of $14.3M
    MT Newswires · 2026/11/9
  • Rating change
    H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/10/20
  • Rating change
    UBS Initiates Ocular Therapeutix(OCUL.US) With Buy Rating, Announces Target Price $14
    Market Newswire · 2026/10/12
  • Rating change
    Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23
    Market Newswire · 2026/6/25
  • Rating change
    Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/6/18
  • Rating change
    H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/4/30
  • Rating change
    Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/5/7
  • H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/11/10
  • Rating change
    A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $30
    Market Newswire · 2026/5/6
  • BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/11/10
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)
    TipRanks · 2026/6/19
  • Rating change
    Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28
    Market Newswire · 2026/8/18
  • Rating change
    RBC Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/7/30
  • Needham Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/9/29
  • BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/10/13
  • Rating change
    Analysts Conflicted on These Healthcare Names: Ocular Therapeutix (OCUL) and Aardvark Therapeutics, Inc. (AARD)
    TipRanks · 2026/3/2
  • Rating change
    BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/3/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Ocular Therapeutix discussion 0 comments

Add a comment